Fusen Pharmaceutical Company Limited (HKG:1652)

HKG:1652 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	83.84	21.06	34.85	128.11	81.06
Short-Term Investments	-	-	-	-	0.64
Cash & Short-Term Investments	83.84	21.06	34.85	128.11	81.71
Cash Growth	298.19%	-39.58%	-72.80%	56.79%	-73.86%
Accounts Receivable	121.96	113.88	183.48	247.19	157.58
Other Receivables	82.38	121.87	114.15	66.85	103.61
Receivables	204.34	235.75	297.63	314.04	261.19
Inventory	192.82	174.72	184.2	123.49	128.97
Prepaid Expenses	-	-	5.49	-	-
Other Current Assets	13.7	28.09	44.63	48.43	37.35
Total Current Assets	494.69	459.61	566.8	614.06	509.22
Property, Plant & Equipment	550.37	621.33	562.18	529.75	506.03
Long-Term Investments	58.92	43.88	148.97	178.31	198.06
Other Intangible Assets	28.03	28.14	22.55	0.48	0.68
Long-Term Deferred Tax Assets	2.48	6.64	5.02	5.08	5.63
Other Long-Term Assets	128.94	78.57	38.22	22.6	19.7
Total Assets	1,263	1,238	1,344	1,350	1,239

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	148.16	123.47	167.55	163.61	102.12
Accrued Expenses	200.4	160.84	147.32	157.57	143.76
Short-Term Debt	4.61	4.61	4.61	230.45	150.52
Current Portion of Long-Term Debt	293.28	303.54	236.56	-	20
Current Portion of Leases	0.46	0.92	1.09	2.11	1.83
Current Income Taxes Payable	5.12	5.51	6.09	7.15	-
Current Unearned Revenue	2.68	10.57	3.9	67.55	4.62
Other Current Liabilities	221.95	164.63	97.43	93.65	66.42
Total Current Liabilities	876.65	774.07	664.52	722.08	489.27
Long-Term Debt	7	79.1	105.7	-	76
Long-Term Leases	0.49	0.13	0.77	0.43	1.94
Long-Term Unearned Revenue	21.37	16.5	10.23	11.32	10.51
Long-Term Deferred Tax Liabilities	-	-	0.3	3.54	4.68
Total Liabilities	905.51	869.8	781.52	737.38	582.39

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	6.18	6.18	6.31	6.38	6.48
Additional Paid-In Capital	224.23	224.23	230.78	246.73	259.46
Retained Earnings	95.45	103.82	292.61	328.88	363.49
Treasury Stock	-	-	-0.08	-0.05	-0.04
Comprehensive Income & Other	33.39	35.44	33.91	32.22	28.79
Total Common Equity	359.25	369.67	563.52	614.17	658.17
Minority Interest	-1.33	-1.31	-1.29	-1.27	-1.23
Shareholders' Equity	357.92	368.36	562.23	612.89	656.94
Total Liabilities & Equity	1,263	1,238	1,344	1,350	1,239

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	305.84	388.3	348.72	232.99	250.29
Net Cash (Debt)	-221.99	-367.24	-313.87	-104.88	-168.59
Net Cash Growth	-	-	-	-	-
Net Cash Per Share	-0.30	-0.50	-0.42	-0.14	-0.22
Filing Date Shares Outstanding	739.3	739.3	745.04	758.21	764.82
Total Common Shares Outstanding	739.3	739.3	745.04	758.21	764.82
Working Capital	-381.95	-314.46	-97.72	-108.03	19.96
Book Value Per Share	0.49	0.50	0.76	0.81	0.86
Tangible Book Value	331.22	341.54	540.97	613.68	657.49
Tangible Book Value Per Share	0.45	0.46	0.73	0.81	0.86
Buildings	297.8	294.82	278.2	278.02	220.23
Machinery	193.54	246.2	204.33	144.85	142.73
Construction In Progress	28.28	21.93	3.46	0.58	4.79

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 24, 2026

Data Sources Report a data error